Your browser doesn't support javascript.
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Lozano-Ojalvo, Daniel; Camara, Carmen; Lopez-Granados, Eduardo; Nozal, Pilar; Del Pino-Molina, Lucía; Bravo-Gallego, Luz Yadira; Paz-Artal, Estela; Pion, Marjorie; Correa-Rocha, Rafael; Ortiz, Alberto; Lopez-Hoyos, Marcos; Iribarren, Marta Erro; Portoles, Jose; Rojo-Portoles, Maria Pilar; Ojeda, Gloria; Cervera, Isabel; Gonzalez-Perez, Maria; Bodega-Mayor, Irene; Montes-Casado, Maria; Portoles, Pilar; Perez-Olmeda, Mayte; Oteo, Jesus; Sanchez-Tarjuelo, Rodrigo; Pothula, Venu; Schwarz, Megan; Brahmachary, Manisha; Tan, Anthony Tanoto; Le Bert, Nina; Berin, Cecilia; Bertoletti, Antonio; Guccione, Ernesto; Ochando, Jordi.
  • Lozano-Ojalvo D; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Camara C; Department of Immunology, Hospital La Paz, 28046 Madrid, Spain.
  • Lopez-Granados E; Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain.
  • Nozal P; Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain; Complement Research Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain.
  • Del Pino-Molina L; Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain.
  • Bravo-Gallego LY; Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain.
  • Paz-Artal E; Department of Immunology, Hospital 12 de Octubre, 28041 Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Pion M; Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain.
  • Correa-Rocha R; Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain.
  • Ortiz A; Department of Nephrology, IIS-Fundación Jimenez Díaz, 28040 Madrid, Spain.
  • Lopez-Hoyos M; Department of Immunology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
  • Iribarren ME; Department of Pneumology, Hospital Puerta de Hierro, 28220 Madrid, Spain.
  • Portoles J; Department of Nephrology, Hospital Puerta de Hierro, 28220 Madrid, Spain.
  • Rojo-Portoles MP; Centro de Salud, Esquivias, 45221 Toledo, Spain.
  • Ojeda G; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Cervera I; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Gonzalez-Perez M; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Bodega-Mayor I; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Montes-Casado M; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Portoles P; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
  • Perez-Olmeda M; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Oteo J; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain.
  • Sanchez-Tarjuelo R; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Pothula V; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
  • Schwarz M; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
  • Brahmachary M; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
  • Tan AT; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore.
  • Le Bert N; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore.
  • Berin C; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Bertoletti A; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore.
  • Guccione E; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: ernesto.guccione@mssm.edu.
  • Ochando J; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic add
Cell Rep ; 36(8): 109570, 2021 08 24.
Article in English | MEDLINE | ID: covidwho-1356159
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / T-Lymphocytes / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109570

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / T-Lymphocytes / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109570